Scientific Approach


F-star develops novel bispecific antibodies to improve the treatment of serious diseases, with a focus on immuno-oncology.

IMG 4765 Resized

Tim D. Jones, Paul J. Carter, Andreas Plückthun, Max Vásquez, Robert G.E.Holgate, Isidro Hötzel, Andrew G. Popplewell, Paul W.H.I. Parren, Markus Enzelberger, Hendrik J. Rademaker, Michael R. Clark, David C. Lowe, Bassil I. Dahiyat, Victoria Smith, John M. Lambert, Herren Wu, Mary Reilly, John S.Haurum, Stefan Dübel, James S. Huston, Thomas Schirrmann, Richard A.J.Janssen, Martin Steegmaier, Jane A. Gross, Andrew R.M. Bradbury, Dennis R. Burton, Dimiter S. Dimitrov, Kerry A. Chester, Martin J. Glennie, Julian Davies, Adam Walker, Steve Martin, John McCafferty & Matthew P. Baker (2015) – The The INNs and outs of antibody non-proprietary names. mAbs 1-9 Nov.1.

Nature Biopharma Dealmarkers, 2 November 2015: Transformative bispecific antibody technology.

Leung, K., Batey, S., Rowlands, R., Isaac, S.J., Jones, P., Drewett, V., Carvalho, J., Gaspar, M., Weller, S., Medcalf, M., Wydro, M.M., Pegram, R., Mudde, G.C., Bauer, A., Moulder, K., Woisetschläger, M., Tuna, M., Haurum, J.S., Sun, S. (2015) A HER2-specific modified Fc fragment (Fcab) induces anti-tumour effects through degradation of HER2 and apoptosis. Mol. Ther. 23 (10).

Kainer, M., Antes, B., Wiederkum, S., Wozniak-Knopp, G., Bauer, A., Rüker, F., Woisetschläger, M. (2012) Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab). Arch. Biochem. Biophys. 526, 154-158.

Woisetschläger, M., Antes, B., Borrowdale, R., Wiederkum, S., Kainer, M., Steinkellner, H., Wozniak-Knopp, G., Moulder, K., Rüker, F., Mudde, G.C., (2013) Functional in vitro and in vivo characterization of an immunoglobulin Fc fragment with engineered Her-2/neu binding sites.

Matthew Kraman, Katarzyna Kmiecik, Carlo Zimarino, Mustapha Faroudi, Katy Everett, Mateusz Wydro, Jacqueline Doody (2016) - A LAG-3/PD-L1 bispecific antibody inhibits tumour growth in two syngeneic colon carcinoma models.
Poster at the annual SITC (Society for Immunotherapy of Cancer) 2016 meeting, National Harbor, Maryland, USA

Lobner, E., Traxlmayr, MW., Obinger, C., Hasenhindl C, (2016) Engineered IgG1-Fc--one fragment to bind them all. Immunol Rev. 2016 Mar;270(1):113-31

Wozniak-Knopp, G., Bartl, S., Bauer, A., Mostageer, M., Woisetschläger, M., Antes, B., Ettl, K., Kainer, M., Weberhofer, G., Wiederkum, S., Himmler, G., Mudde, G.C., Rüker, F. (2010) Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng. Des. Sel. 23, 289-297.

Traxlmayr, M., Wozniak-Knopp, G., Stadlmayr, G., Rüker, F., Obinger, C. (2011) Integrin binding human antibody constant domains - probing the C-terminal structural loops for grafting the RGD motif. J. Biotechnol. 155, 193-202.

Jez, J., Antes, B., Castilho, A., Kainer, M., Wiederkum, S., Grass, J., Rüker, F., Woisetschläger, M., Steinkellner, H. (2012) Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments. J. Biol. Chem. 287, 24313-24319.

Rüker, F. (2012) Guest editor's introduction for special issue on antibody engineering. Arch. Biochem. Biophys. 526, 85-86.

Traxlmayr, M.W., Obinger, C. (2012a) Directed evolution of proteins for increased stability and expression using yeast display. Arch. Biochem. Biophys. 526, 174-180.

Traxlmayr, M.W., Faissner, M., Stadlmayr, G., Hasenhindl, C., Antes, B., Rüker, F., Obinger, C. (2012b) Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast. Biochim. Biophys. Acta 1824, 542-549.

Lai, B., Hasenhindl, C., Obinger, C., Oostenbrink, C. 2014. Molecular dynamics simulation of the crystallisable fragment of IgG1-insights for the design of Fcabs. Int. J. Mol. Sci. 15, 438-455.

Traxlmayr, M. W., Lobner, E., Stadlmayr, G., Hasenhindl, C., Antes, B., Rüker, F., Obinger, C. (2013) Construction of a pH-sensitive Her2-binding IgG1-Fc by directed evolution. Biotechnol. J.

Wozniak-Knopp, G., Rüker, F. (2012) A C-terminal interdomain disulfide bond significantly stabilizes the Fc fragment of IgG. Arch. Biochem. Biophys. 526, 181-187.

Wozniak-Knopp, G., Stadlmann, J., Rüker, F. (2012) Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds. PLoS One. 2012;7(1):e30083.

Traxlmayr, M.W., Lobner, E., Antes, B., Kainer, M., Wiederkum, S., Hasenhindl, C., Stadlmayr, G., Rüker, F., Woisetschläger, M., Moulder, K., Obinger, C. (2013) Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display. Protein Eng. Des. Sel. 26, 255-265.

Hasenhindl, C., Traxlmayr, M.W., Wozniak-Knopp, G., Jones, P.C., Stadlmayr, G., Rüker, F., Obinger, C. (2013) Stability assessment on a library scale – a rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc. Protein Eng. Des. Sel. 26, 675-682.

Lai, B., Hasenhindl, C., Obinger, C., Oostenbrink, C. (2013) Structure and dynamics of an antibody Fc fragment from molecular dynamics simulations. Biotechnol. J.

Stadlmayr, G., Wozniak-Knopp, G., Hasenhindl, C., Schaffner, I., Traxlmayr, M. W., Rüker, F., Obinger, C. (2013) Stability engineering of IgG1-Fc based on computational analysis and rational design. Proteins.

Doerner, A., Rheil, L., Zielonka, S., Kolmar, H. (2013) Therapeutic antibody engineering by high efficiency cell screening. FEBS Lett

Wang, L., He, Y., Zhang, G., Ma, J., Liu, C., He, W., Wang, W., Han, H., Boruah, B.H., Gao, B. (2013) Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody. PLoS ONE 8(9): e75589.

Rüker, F., Wozniak-Knopp, G. (2010) Engineering antigen binding sites into the Fc region of IgG. In Bioorbis (Ed.) Advancing Protein Therapeutics, Frankfurt, Germany.

Rüker, F., Wozniak-Knopp, G. (2009) Engineering of non-CDR loops in immunoglobulin domains. In: Little, M. (Ed.), Recombinant Antibodies for Immunotherapy Part VI, 231-242; Cambridge University Press, New York; ISBN 978-0-521-88732-8.